The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma

Brunello, Eleonora, Bogina, Giuseppe, Bria, Emilio, Vergine, Marco, Zamboni, Giuseppe, Pedron, Serena, Daniele, Isabella, Furlanetto, Jenny, Carbognin, Luisa, Marconi, Marcella, Manfrin, Erminia, Ibrahim, Merdol, Miller, Keith, Tortora, Giampaolo, Molino, Annamaria, Jasani, Bharat, Beccari, Serena, Bonetti, Franco, Chilosi, Marco, Martignoni, Guido and Brunelli, Matteo 2013. The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma. Journal of Cancer Research and Clinical Oncology 139 (9) , pp. 1563-1568. 10.1007/s00432-013-1479-0

Full text not available from this repository.

Abstract

Purpose: Triple (ER-, PR-, HER2-) negative breast carcinoma lack targeted therapies, making this group of tumors difficult to treat. By definition, the lack of HER2 expression means a case scoring 0 or 1+ after immunophenotypical analysis and makes the patients avoiding therapeutical chances with anti-HER2 inhibitors. We sought to recruit from a group of triple negative breast carcinoma, patients eligible for effective personalized targeted therapy with anti-HER therapies on the basis of their HER2 gene status. Methods: 135 patients diagnosed with IHC triple negative breast carcinoma were studied. Whole tissue sections were used for in situ hybridization analysis. Results: 8/100 (8 %) of ductal-type triple negative breast carcinoma presented Her-2/neu gene amplification versus 2/35 (5.7 %) non-ductal triple negative breast carcinoma. Three cases showed a ratio 2.5. One case showed Her-2/neu heterogeneous gene amplification, ratio 2.3. The other six showed from 7 to 8 absolute Her-2/neu gene copy number. Two cases staged pT1c, and eight cases staged pT2. Eight cases graded G3 and two cases G2. Conclusion: (1) Eight percentage of ductal and 5.7 % non-ductal-type triple negative breast carcinoma present Her-2/neu gene amplification, (2) the standard diagnostic flowchart “do not FISH in 0–1+ (HER2-) breast carcinoma” should be replaced by “do FISH in triple (ER-, PR-, HER2-) negative breast carcinoma,” to avoid loss of therapeutical chances in a cohort of such a patients, (3) we demonstrated the identification of a small but significant subset of patients targetable with anti-HER2 inhibitors, giving patients affected by (ex)triple negative breast carcinoma new personalized therapeutical chances.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RG Gynecology and obstetrics
Uncontrolled Keywords:	Triple negative breast carcinoma; Her-2/neu gene amplification; In situ hybridization; Trastuzumab
Publisher:	Springer
ISSN:	0171-5216
Last Modified:	18 Mar 2023 02:08
URI:	https://orca.cardiff.ac.uk/id/eprint/61465

Citation Data

Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item